KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Total Liabilities

Last Annual Value

42.92M

3-Year CAGR

8%

5-Year CAGR

19%

10-Year CAGR

9%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Liabilities

KLRS · NASDAQ
CompanyTotal Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
42.92M
-3.9%-6.9%N/A 
20.27M
-28.8%6.5%18.4%
20.97M
-57.2%-39.5%N/A
8.64M
-16.5%-20.3%N/A
8.02M
24.1%21.5%N/A
62.51M
-25.3%-18.6%N/A
109.13M
7.2%-2.5%19.1%
33.06M
-14.5%14.1%N/A
111.94M
-34.7%-18.5%N/A
10.51M
-27.4%-7.0%N/A
31.12M
-18.6%22.1%6.5%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66